Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Rhea-AI Summary
Madrigal Pharmaceuticals (NASDAQ: MDGL) will participate in three investor conference fireside chats in late November and early December 2025. Presentations and live webcasts are scheduled as follows: Jefferies Global Healthcare Conference in London on Nov 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET); Evercore Healthcare Conference on Dec 2, 2025 at 4:15 P.M. ET; and Piper Sandler Healthcare Conference on Dec 3, 2025 at 1:30 P.M. ET. All fireside chats will be webcast live and can be accessed via Madrigal’s Investor Relations Events page.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MDGL gained 4.57%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
Jefferies Global Healthcare Conference in London
Thursday, Nov. 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET)
The presentation will be webcast live and may be accessed here.
8th Annual Evercore Healthcare Conference
Tuesday, Dec. 2, 2025 at 4:15 P.M. ET
The presentation will be webcast live and may be accessed here.
Piper Sandler 37th Annual Healthcare Conference
Wednesday, Dec. 3, 2025 at 1:30 P.M. ET
The presentation will be webcast live and may be accessed here.
The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When will Madrigal (MDGL) present at the Jefferies Global Healthcare Conference?
How can investors watch Madrigal (MDGL) at the Evercore Healthcare Conference on Dec 2, 2025?
What time is Madrigal (MDGL) scheduled at the Piper Sandler Healthcare Conference on Dec 3, 2025?
Will Madrigal (MDGL) webcast all three conference presentations?
Where can I find the live webcasts and replays of Madrigal (MDGL) conference presentations?
